The Filings Report

HCA Healthcare, Inc.

HCANYSECIK 860730Healthcare / Healthcare Providers & Servicesfiscal year ends December67 quarters since 2010

Revenue, Q3 FY2026
$19.8B
+3.6% on Q3 FY2025
Net income
$1.6B
−3.9% on Q3 FY2025
Free cash flow
$3.1B
−0.8% on Q3 FY2025
Diluted EPS
$7.27
+4.5% on Q3 FY2025
Revenue, TTM
$78.7B
trailing four quarters
Net margin, TTM
8.6%
net income $6.8B
Free cash flow, TTM
$6.0B
$11.2B less $5.2B capex
Cash and equivalents
$908M
long-term debt $42.4B, Sep 30, 2026
Shares, 12-month change
−8.5%
209M shares, Sep 30, 2026
Buybacks, TTM
$9.2B
9.3% of market value
Dividends, TTM
$681M
0.7% of market value
Market value
$98.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, HCA Healthcare, Inc. reported revenue of $19.8B, +3.6% on Q3 FY2025, and net income of $1.6B (−3.9%). Free cash flow, operating cash flow less capital expenditures, was $3.1B ($4.5B less $1.4B). Diluted earnings per share were $7.27.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
$0$10B$20B$30BQ4'22, Revenue: $15.5BQ4'22, Net income: $2.1BQ4'22Q1'23, Revenue: $15.6BQ1'23, Net income: $1.4BQ1'23Q2'23, Revenue: $15.9BQ2'23, Net income: $1.2BQ2'23Q3'23, Revenue: $16.2BQ3'23, Net income: $1.1BQ3'23Q4'23, Revenue: $17.3BQ4'23, Net income: $1.6BQ4'23Q1'24, Revenue: $17.3BQ1'24, Net income: $1.6BQ1'24Q2'24, Revenue: $17.5BQ2'24, Net income: $1.5BQ2'24Q3'24, Revenue: $17.5BQ3'24, Net income: $1.3BQ3'24Q4'24, Revenue: $18.3BQ4'24, Net income: $1.4BQ4'24Q1'25, Revenue: $18.3BQ1'25, Net income: $1.6BQ1'25Q2'25, Revenue: $18.6BQ2'25, Net income: $1.7BQ2'25Q3'25, Revenue: $19.2BQ3'25, Net income: $1.6BQ3'25Q4'25, Revenue: $19.5BQ4'25, Net income: $1.9BQ4'25Q1'26, Revenue: $19.1BQ1'26, Net income: $1.6BQ1'26Q2'26, Revenue: $20.2BQ2'26, Net income: $1.7BQ2'26Q3'26, Revenue: $19.8BQ3'26, Net income: $1.6BQ3'26$0$10B$20B$30BQ4'22, Revenue: $15.5BQ4'22, Net income: $2.1BQ1'23, Revenue: $15.6BQ1'23, Net income: $1.4BQ1'23Q2'23, Revenue: $15.9BQ2'23, Net income: $1.2BQ3'23, Revenue: $16.2BQ3'23, Net income: $1.1BQ3'23Q4'23, Revenue: $17.3BQ4'23, Net income: $1.6BQ1'24, Revenue: $17.3BQ1'24, Net income: $1.6BQ1'24Q2'24, Revenue: $17.5BQ2'24, Net income: $1.5BQ3'24, Revenue: $17.5BQ3'24, Net income: $1.3BQ3'24Q4'24, Revenue: $18.3BQ4'24, Net income: $1.4BQ1'25, Revenue: $18.3BQ1'25, Net income: $1.6BQ1'25Q2'25, Revenue: $18.6BQ2'25, Net income: $1.7BQ3'25, Revenue: $19.2BQ3'25, Net income: $1.6BQ3'25Q4'25, Revenue: $19.5BQ4'25, Net income: $1.9BQ1'26, Revenue: $19.1BQ1'26, Net income: $1.6BQ1'26Q2'26, Revenue: $20.2BQ2'26, Net income: $1.7BQ3'26, Revenue: $19.8BQ3'26, Net income: $1.6BQ3'26

Net income losses drawn in red.

Free cash flow
$0$1B$2B$3B$4BQ4'22, Free cash flow: $1.2BQ4'22Q1'23, Free cash flow: $606MQ1'23Q2'23, Free cash flow: $1.2BQ2'23Q3'23, Free cash flow: $1.3BQ3'23Q4'23, Free cash flow: $1.5BQ4'23Q1'24, Free cash flow: $1.4BQ1'24Q2'24, Free cash flow: $690MQ2'24Q3'24, Free cash flow: $2.3BQ3'24Q4'24, Free cash flow: $1.3BQ4'24Q1'25, Free cash flow: $660MQ1'25Q2'25, Free cash flow: $3.0BQ2'25Q3'25, Free cash flow: $3.1BQ3'25Q4'25, Free cash flow: $870MQ4'25Q1'26, Free cash flow: $895MQ1'26Q2'26, Free cash flow: $1.1BQ2'26Q3'26, Free cash flow: $3.1BQ3'26$0$1B$2B$3B$4BQ4'22, Free cash flow: $1.2BQ1'23, Free cash flow: $606MQ1'23Q2'23, Free cash flow: $1.2BQ3'23, Free cash flow: $1.3BQ3'23Q4'23, Free cash flow: $1.5BQ1'24, Free cash flow: $1.4BQ1'24Q2'24, Free cash flow: $690MQ3'24, Free cash flow: $2.3BQ3'24Q4'24, Free cash flow: $1.3BQ1'25, Free cash flow: $660MQ1'25Q2'25, Free cash flow: $3.0BQ3'25, Free cash flow: $3.1BQ3'25Q4'25, Free cash flow: $870MQ1'26, Free cash flow: $895MQ1'26Q2'26, Free cash flow: $1.1BQ3'26, Free cash flow: $3.1BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60BQ4'22, Cash and equivalents: $908MQ4'22, Long-term debt: $37.7BQ4'22Q1'23, Cash and equivalents: $842MQ1'23, Long-term debt: $36.5BQ1'23Q2'23, Cash and equivalents: $862MQ2'23, Long-term debt: $36.5BQ2'23Q3'23, Cash and equivalents: $891MQ3'23, Long-term debt: $36.8BQ3'23Q4'23, Cash and equivalents: $935MQ4'23, Long-term debt: $37.2BQ4'23Q1'24, Cash and equivalents: $1.3BQ1'24, Long-term debt: $37.2BQ1'24Q2'24, Cash and equivalents: $831MQ2'24, Long-term debt: $36.3BQ2'24Q3'24, Cash and equivalents: $2.9BQ3'24, Long-term debt: $38.3BQ3'24Q4'24, Cash and equivalents: $1.9BQ4'24, Long-term debt: $38.3BQ4'24Q1'25, Cash and equivalents: $1.1BQ1'25, Long-term debt: $41.1BQ1'25Q2'25, Cash and equivalents: $939MQ2'25, Long-term debt: $39.4BQ2'25Q3'25, Cash and equivalents: $997MQ3'25, Long-term debt: $38.4BQ3'25Q4'25, Cash and equivalents: $1.0BQ4'25, Long-term debt: $41.6BQ4'25Q1'26, Cash and equivalents: $940MQ1'26, Long-term debt: $39.5BQ1'26Q2'26, Cash and equivalents: $1.0BQ2'26, Long-term debt: $43.5BQ2'26Q3'26, Cash and equivalents: $908MQ3'26, Long-term debt: $42.4BQ3'26$0$20B$40B$60BQ4'22, Cash and equivalents: $908MQ4'22, Long-term debt: $37.7BQ1'23, Cash and equivalents: $842MQ1'23, Long-term debt: $36.5BQ1'23Q2'23, Cash and equivalents: $862MQ2'23, Long-term debt: $36.5BQ3'23, Cash and equivalents: $891MQ3'23, Long-term debt: $36.8BQ3'23Q4'23, Cash and equivalents: $935MQ4'23, Long-term debt: $37.2BQ1'24, Cash and equivalents: $1.3BQ1'24, Long-term debt: $37.2BQ1'24Q2'24, Cash and equivalents: $831MQ2'24, Long-term debt: $36.3BQ3'24, Cash and equivalents: $2.9BQ3'24, Long-term debt: $38.3BQ3'24Q4'24, Cash and equivalents: $1.9BQ4'24, Long-term debt: $38.3BQ1'25, Cash and equivalents: $1.1BQ1'25, Long-term debt: $41.1BQ1'25Q2'25, Cash and equivalents: $939MQ2'25, Long-term debt: $39.4BQ3'25, Cash and equivalents: $997MQ3'25, Long-term debt: $38.4BQ3'25Q4'25, Cash and equivalents: $1.0BQ4'25, Long-term debt: $41.6BQ1'26, Cash and equivalents: $940MQ1'26, Long-term debt: $39.5BQ1'26Q2'26, Cash and equivalents: $1.0BQ2'26, Long-term debt: $43.5BQ3'26, Cash and equivalents: $908MQ3'26, Long-term debt: $42.4BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

HCA Healthcare, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 28, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue19,84920,23019,10919,51319,16118,60518,32118,285+3.6%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative146148133153139130126120+5.0%
Operating income—————————
Other income (expense)—————————
Pretax income2,3702,4942,2872,6722,4182,4152,3272,133−2.0%
Income tax521564430509515524502447+1.2%
Net income1,5791,6991,6201,8781,6431,6531,6101,438−3.9%
Diluted EPS ($)7.277.627.15—6.966.836.45—+4.5%
Diluted shares (millions)217223227—236242249——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

HCA Healthcare, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 28, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents9081,0139401,0409979391,0601,933−8.9%
Short-term investments—————————
Total current assets16,21917,19016,05215,78315,28515,56316,25816,414+6.1%
Total assets63,45263,25061,45060,72059,74759,53659,79859,513+6.2%
Total current liabilities19,77917,31219,25816,35017,89615,93913,63115,177+10.5%
Long-term debt42,40043,45439,49141,60338,40139,37941,05738,333+10.4%
Total liabilities—————————
Stockholders’ equity(8,077)(6,642)(6,303)(6,027)(5,335)(4,394)(3,519)(2,499)−51.4%
Shares outstanding (millions)209217222224228234241248—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

HCA Healthcare, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 28, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow4,4612,3352,0142,3594,4164,2101,6512,559+1.0%
Capital expenditures1,3571,2311,1191,4891,2881,1769911,285+5.4%
Free cash flow (CFO − capex)3,1041,1048958703,1283,0346601,274−0.8%
Depreciation and amortization954944930911889863860856+7.3%
Share repurchases2,9702,0641,5712,5582,4982,5052,5061,700+18.9%
Dividends paid165171183162166171180165−0.6%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 10, 2026.

Income statement

HCA Healthcare, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed May 11, 2011FY2009ended Dec 31, 2009filed May 11, 2011
Revenue75,60070,60364,96860,23358,75251,53351,336——————————
Cost of revenue—————————————————
Gross profit—————————————————
Research and development—————————————————
Selling, general and administrative548421353307337416370344340343327285287248228182164
Operating income—————————————————
Other income (expense)—————————————————
Pretax income9,8328,5237,7068,5809,8335,4305,2445,3354,3814,8103,9573,4812,946————
Income tax2,0501,8661,6151,7462,1121,0431,0999461,6381,3781,2611,108950888719658627
Net income6,7845,7605,2425,6436,9563,7543,5053,7872,2162,8902,1291,8751,5561,6052,4651,2071,054
Diluted EPS ($)28.3322.0018.9719.1521.1610.9310.0710.665.957.304.994.163.373.494.972.762.44
Diluted shares (millions)239262276295329344348355372396427450462459496437432

Balance sheet

HCA Healthcare, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed May 11, 2011FY2009ended Dec 31, 2009filed May 11, 2011
Cash and equivalents1,0401,9339359081,4511,793621502732646741566414705373411312
Short-term investments————103116———————————
Total current assets15,78316,41414,92713,64313,54212,33311,19610,2139,9779,0869,2328,9308,0377,7637,2336,919—
Total assets60,72059,51356,21152,43850,74247,49045,05839,20736,59333,75832,74430,98028,59428,07526,89823,852—
Total current liabilities16,35015,17712,6559,9029,5828,7047,7577,5696,1585,8345,5165,4805,6956,1725,5544,269—
Long-term debt41,60338,33337,16937,71434,34230,79533,57732,03332,85831,16030,25529,08827,59027,49525,64527,633—
Total liabilities——————45,62342,12541,58839,39138,79037,47835,75936,41633,912——
Stockholders’ equity(6,027)(2,499)(1,774)(2,767)(933)572(2,808)(4,950)(6,806)(7,302)(7,599)(7,894)(8,270)(9,660)(8,258)11,926—
Shares outstanding (millions)224248264277304340338342350370397421441444438516—

Cash flow statement

HCA Healthcare, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed May 11, 2011FY2009ended Dec 31, 2009filed May 11, 2011
Operating cash flow12,63610,5149,4318,5228,9599,2327,6026,7615,4265,653—4,4483,6804,1753,9333,0852,747
Capital expenditures4,9444,8754,7444,3953,5772,8354,1583,5733,0152,7602,3752,1761,9431,8621,6791,3251,317
Free cash flow (CFO − capex)7,6925,6394,6874,1275,3826,3973,4443,1882,4112,893—2,2721,7372,3132,2541,7601,430
Depreciation and amortization3,5233,3123,0772,9692,8532,7212,5962,2782,1311,9661,9041,8201,7531,6791,4651,4211,425
Share repurchases10,0676,0423,8117,0008,2154411,0311,5302,0512,7512,3971,750500—1,503——
Dividends paid6796906616536241535504870——7163,148314,257—

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$31M
13 sales by 5 insiders; officers and directors $31M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 26, 2026McAlevey Michael REVP & Chief Legal & Admin Off.otherindirect7,769$429.00$3M0Aug 28, 2026
May 7, 2026Marks Mike AEVP and CFOgift3,336$0.00—0May 11, 2026
May 7, 2026Marks Mike AEVP and CFOgiftindirect3,336$0.00—46,576May 11, 2026
Apr 28, 2026Frist William RDirector, 10% owneraward809$0.00—13,740Apr 30, 2026
Apr 28, 2026Frist Thomas F IIIDirector, 10% owneraward1,041$0.00—15,858Apr 30, 2026
Apr 28, 2026Smith Andrea BDirectoraward509$0.00—4,666Apr 30, 2026
Apr 28, 2026Riley Wayne JosephDirectoraward509$0.00—15,029Apr 30, 2026
Apr 28, 2026Michelson Michael WDirectoraward925$0.00—12,576Apr 30, 2026
Apr 28, 2026Johnston Hugh FDirectoraward809$0.00—4,475Apr 30, 2026
Apr 28, 2026Deparle Nancy AnnDirectoraward509$0.00—21,910Apr 30, 2026
Apr 28, 2026Chidsey JohnDirectoraward809$0.00—1,305Apr 30, 2026
Feb 18, 2026McAlevey Michael REVP & Chief Legal & Admin Off.open-market sale1,694$533.37$904K8,853Feb 18, 2026
Feb 13, 2026McAlevey Michael REVP & Chief Legal & Admin Off.tax withholding3,306$540.29$2M10,547Feb 18, 2026
Feb 13, 2026McAlevey Michael REVP & Chief Legal & Admin Off.option exercise5,000$236.61$1M13,853Feb 18, 2026
Feb 11, 2026Wyatt Christopher F.SVP & Controlleropen-market sale4,000$505.00$2M44,379Feb 12, 2026
Feb 11, 2026Berres JenniferSVP & Chief Human Res. Officeropen-market sale4,010$526.16$2M11,993Feb 12, 2026
Feb 11, 2026Berres JenniferSVP & Chief Human Res. Officeropen-market sale4,010$503.00$2M16,003Feb 12, 2026
Feb 10, 2026Wyatt Christopher F.SVP & Controlleraward3,350$0.00—49,413Feb 12, 2026
Feb 10, 2026Wyatt Christopher F.SVP & Controllertax withholding1,034$502.05$519K48,379Feb 12, 2026
Feb 10, 2026Rossitto EricaSVP & Chief Nurse Executivetax withholding418$502.05$210K10,407Feb 12, 2026
Feb 10, 2026Rossitto EricaSVP & Chief Nurse Executiveaward1,676$0.00—10,825Feb 12, 2026
Feb 10, 2026McAlevey Michael REVP & Chief Legal & Admin Off.award8,372$0.00—11,859Feb 12, 2026
Feb 10, 2026McAlevey Michael REVP & Chief Legal & Admin Off.tax withholding3,006$502.05$2M8,853Feb 12, 2026
Feb 10, 2026Marks Mike AEVP and CFOtax withholding1,690$502.05$848K3,336Feb 12, 2026
Feb 10, 2026Marks Mike AEVP and CFOaward5,026$0.00—5,026Feb 12, 2026

Full insider history for HCA Healthcare, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
HCA Healthcare, Inc., CIK 860730 on EDGAR
Extract generated
October 30, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends, PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated October 30, 2026.

JSON file
/data/financials/HCA.json